Biotechnology
Compare Stocks
2 / 10Stock Comparison
TTRX vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
TTRX vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $112M | $9.63B |
| Revenue (TTM) | — | $-92K |
| Net Income (TTM) | $-2M | $-327M |
| Total Debt | $121K | $110K |
| Cash & Equiv. | $873K | $357M |
Quick Verdict: TTRX vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TTRX is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.45
- Lower volatility, beta 1.45, current ratio 1.55x
- Beta 1.45, current ratio 1.55x
PRAX carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -20.1% 10Y total return vs TTRX's -45.8%
- 2.4% margin vs TTRX's 1.4%
- +7.7% vs TTRX's -45.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Quality / Margins | 2.4% margin vs TTRX's 1.4% | |
| Stability / Safety | Beta 1.45 vs PRAX's 1.55 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +7.7% vs TTRX's -45.8% | |
| Efficiency (ROA) | -40.2% ROA vs TTRX's -87.1% |
TTRX vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
TTRX vs PRAX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | — | -$92,000 |
| EBITDAEarnings before interest/tax | — | -$357M |
| Net IncomeAfter-tax profit | — | -$327M |
| Free Cash FlowCash after capex | — | -$283M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | +2.7% |
Valuation Metrics
Insufficient data to determine a leader in this category.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $112M | $9.6B |
| Enterprise ValueMkt cap + debt − cash | $111M | $9.3B |
| Trailing P/EPrice ÷ TTM EPS | — | -24.72x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | — | 8.54x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
PRAX leads this category, winning 4 of 4 comparable metrics.
Profitability & Efficiency
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | -43.0% |
| ROA (TTM)Return on assets | -87.1% | -40.2% |
| ROICReturn on invested capital | — | -65.0% |
| ROCEReturn on capital employed | -125.5% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | -$751,563 | -$357M |
| Cash & Equiv.Liquid assets | $872,599 | $357M |
| Total DebtShort + long-term debt | $121,036 | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRAX five years ago would be worth $7,918 today (with dividends reinvested), compared to $5,421 for TTRX. Over the past 12 months, PRAX leads with a +775.0% total return vs TTRX's -45.8%. The 3-year compound annual growth rate (CAGR) favors PRAX at 174.9% vs TTRX's -18.5% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -19.1% | +16.4% |
| 1-Year ReturnPast 12 months | -45.8% | +775.0% |
| 3-Year ReturnCumulative with dividends | -45.8% | +1976.5% |
| 5-Year ReturnCumulative with dividends | -45.8% | -20.8% |
| 10-Year ReturnCumulative with dividends | -45.8% | -20.1% |
| CAGR (3Y)Annualised 3-year return | -18.5% | +174.9% |
Risk & Volatility
PRAX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TTRX is the less volatile stock with a 1.45 beta — it tends to amplify market swings less than PRAX's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 93.6% from its 52-week high vs TTRX's 14.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.45x | 1.40x |
| 52-Week HighHighest price in past year | $26.50 | $356.00 |
| 52-Week LowLowest price in past year | $2.57 | $35.18 |
| % of 52W HighCurrent price vs 52-week peak | +14.3% | +93.6% |
| RSI (14)Momentum oscillator 0–100 | 61.1 | 55.6 |
| Avg Volume (50D)Average daily shares traded | 23K | 378K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TTRX as "Buy" and PRAX as "Buy".
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $548.80 |
| # AnalystsCovering analysts | 1 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
PRAX leads in 3 of 6 categories — strongest in Profitability & Efficiency and Total Returns.
TTRX vs PRAX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is TTRX or PRAX a better buy right now?
Analysts rate Turn Therapeutics Inc.
(TTRX) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TTRX or PRAX?
Over the past 5 years, Praxis Precision Medicines, Inc.
(PRAX) delivered a total return of -20. 8%, compared to -45. 8% for Turn Therapeutics Inc. (TTRX). Over 10 years, the gap is even starker: PRAX returned -20. 9% versus TTRX's -45. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TTRX or PRAX?
By beta (market sensitivity over 5 years), Praxis Precision Medicines, Inc.
(PRAX) is the lower-risk stock at 1. 40β versus Turn Therapeutics Inc. 's 1. 45β — meaning TTRX is approximately 4% more volatile than PRAX relative to the S&P 500.
04Which has better profit margins — TTRX or PRAX?
Turn Therapeutics Inc.
(TTRX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Praxis Precision Medicines, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TTRX leads at 0. 0% versus 0. 0% for PRAX. At the gross margin level — before operating expenses — TTRX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — TTRX or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is TTRX or PRAX better for a retirement portfolio?
For long-horizon retirement investors, Praxis Precision Medicines, Inc.
(PRAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (PRAX: -20. 9%, TTRX: -45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between TTRX and PRAX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.